In a strongly worded editorial, the New England Journal of Medicine took issue with ananalysis that had dismissed a link between an active ingredient in the pills and cancer.
One of the most prominent statisticians in the U.S. is taking issue with ananalysis that claims there is no credible evidence the cholesterol drug Vytorin increases the risk of cancer death.